REFERENCES
  1. Antoni S, Ferlay J, Soerjomataram I, et al. Bladder cancer incidence and mortality: A global overview and recent trends.Eur Urol. 2017;71: 96.
  2. Miyazaki J, Nishiyama H. Epidemiology of urothelial carcinoma. Int J Urol. 2017;24:730-34.
  3. Baykan O, Akgul M, Uren N, et al. The Relationship Between Urothelial Type Bladder Cancer, Plasma 25-Hydroxyvitamin D Levels, and Vitamin D Receptor ApaI BsmI FokI, and TaqI Polymorphisms. Clin Lab .2019,65.10.7754/Clin.Lab.2018.180339.
  4. Cumberbatch MGK, Jubber I, Black PC, et al. Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in. 2018. Eur Urol. 2018;74: 784-95.
  5. TNM classification of malignant tumors. UICC International Union Against Cancer. 8th edn. Brierley JD, Gospodarowicz M, Wittekind C (Eds. 2017, Wiley-Blackwell)
  6. Mostafid AH. Time to re‐evaluate and refine re‐transurethral resection in bladder cancer?.BJU international . 2016;118:9-10.
  7. Adiyat KT, Katkoori D, Soloway CT, De Los Santos R, Manoharan M, Soloway MS. “Complete transurethral resection of bladder tumor” are the guidelines being followed? Urology. 2010;75:365-67.
  8. Witjes JA, Moonen PMJ, Van Der Heijden AG. Review pathology in a diagnostic bladder cancer trial: effect of patient risk category. Urology. 2006; 67:751-55.
  9. Babjuk M, Burger M, Compérat E, et al. EAU guidelines on non-muscle-invasive (Ta, T1 and CIS) bladder cancer, in EAU guidelines. 2020, European Association of Urology guidelines office Arnhem, the Netherlands.
  10. Baltacı S, Bozlu M, Yıldırım A, et al. Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette-Guérin. BJU Int. 116(5), 721-726.
  11. Fritsche HM, Burger M, Svatek RS, et al. Characteristics and out- comes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol. 2010;57:300
  12. Herr HW, Donat SM. A re-staging transurethral resection predicts early progression of superficial bladder cancer. BJU Int. 2006;97: 1194:8.
  13. Naselli A, Hurle R, Paparella S, et al. Role of Restaging Transurethral Resection for T1 Non-muscle invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus.2018;4:558-67.
  14. Cumberbatch MGK, Foerster B, Catto JWF, et al. Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review. Eur Urol. 2018;73: 925-33.
  15. Palou J, Pisano F, Sylvester R, Joniau S, Serretta V, Larré S. Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought. World journal of urology. 2018;36:1621-27.
  16. Gaya JM, Palou J, Cosentino M, Patiño D, Rodríguez-Faba O, Villavicencio H. A second transurethral resection could be not necessary in all high grade non-muscle-invasive bladder tumours. Actas Urológicas Españolas (English). 2012:539-44.
  17. Ho HC, Hughes T, Bozlu M, Kadıoğlu A, Somani BK. What do urologists need to know: Diagnosis, treatment, and follow-up during COVID-19 pandemic. Turkish Journal of Urology. 2020;46:169.
  18. Divrik RT, Sahin AF, Yildirim U, Altok M, Zorlu F: Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol.2010;58:185-90.
  19. Sfakianos JP, Kim PH, Hakimi AA, Herr HW. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guerin. J Urol. 2014;191: 341-5.
  20. Gontero P, Sylvester R, Pisano F, et al. The impact of re‐transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high‐grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin. BJU international.2016;118:44-52.
  21. Calò B, Chirico M, Fortunato F, et al. Is repeat transurethral resection always needed in high-grade T1 bladder cancer?. Frontiers in Oncology. 2019;9.
  22. Bishr M, Lattouf JB, Latour M, Saad F. Tumour stage on re-staging transurethral resection predicts recurrence and progression-free survival of patients with high-risk non-muscle invasive bladder cancer. Can Urol Assoc J. 2014;8:306-10.
  23. Witjes J, Bruins HM, Cathomas R, et al. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer, in EAU Guidelines. 2020, European Association of Urology Guidelines Office Arnhem, The Netherlands.